Adam Hickey
Overview
Explore the profile of Adam Hickey including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
9
Citations
370
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Swiha M, Papa N, Sabahi Z, Ayati N, John N, Pathmanandavel S, et al.
J Nucl Med
. 2024 Apr;
65(6):904-908.
PMID: 38637137
Lu-PSMA therapy is an effective treatment in patients with metastatic castration-resistant prostate cancer. SUV is a valuable screening biomarker to assess the suitability for Lu-PSMA therapy but requires quantitative software....
2.
Emmett L, John N, Pathmanandavel S, Counter W, Ayers M, Sharma S, et al.
Ther Adv Med Oncol
. 2023 Mar;
15:17588359231156392.
PMID: 36872949
Background: LuPSMA is an effective treatment in metastatic castrate-resistant prostate cancer with trials adopting a standardised dose interval. Adjusting treatment intervals utilising early response biomarkers may improve patient outcomes. Objective:...
3.
John N, Pathmanandavel S, Crumbaker M, Counter W, Ho B, Yam A, et al.
J Nucl Med
. 2022 Oct;
64(3):410-415.
PMID: 36215568
Lu-PSMA is an effective treatment in metastatic castration-resistant prostate cancer (mCRPC). Our ability to assess response rates and adjust treatment may be improved using predictive tools. This study aimed to...
4.
Pathmanandavel S, Crumbaker M, Ho B, Yam A, Wilson P, Niman R, et al.
J Nucl Med
. 2022 Aug;
64(2):221-226.
PMID: 36008120
Lu-PSMA-617 is an effective and novel treatment in metastatic castration-resistant prostate cancer (mCRPC). Our ability to assess response rates and therefore efficacy may be improved using predictive tools. This study...
5.
Nguyen A, Fullard K, Sheehan-Dare G, Tang R, Chan L, Ho B, et al.
J Med Imaging Radiat Oncol
. 2021 Oct;
66(6):731-737.
PMID: 34676675
Introduction: F-Fludeoxyglucose PET-CT (FDG) is increasingly used to stage breast cancer. Most breast cancers express the Oestrogen Receptor (ER) and Progesterone Receptor (PR), and this subtype demonstrates lower activity on...
6.
Nandurkar R, van Leeuwen P, Stricker P, Woo H, Kooner R, Yuen C, et al.
Br J Radiol
. 2018 Dec;
92(1095):20180667.
PMID: 30563350
Methods:: We analysed results of 142 males with staging PSMA prior to radical prostatectomy (RP). Data collected included PSMA PET/CT, bone scan (30/142), mpMRI (112/142), and pathological T stage (pT)...
7.
Emmett L, Yin C, Crumbaker M, Hruby G, Kneebone A, Epstein R, et al.
J Nucl Med
. 2018 Dec;
60(7):950-954.
PMID: 30552200
Prostate-specific membrane antigen (PSMA) may be targeted for both diagnostic and therapeutic purposes in the management of prostate cancer (PCa). In preclinical models, androgen blockade (AB) increases expression of PSMA...
8.
Morigi J, Stricker P, van Leeuwen P, Tang R, Ho B, Nguyen Q, et al.
J Nucl Med
. 2015 Jun;
56(8):1185-90.
PMID: 26112024
Unlabelled: In prostate cancer with biochemical failure after therapy, current imaging techniques have a low detection rate at the prostate-specific antigen (PSA) levels at which targeted salvage therapy is effective....
9.
Chan W, Ramsay S, Szeto E, Freund J, Pohlen J, Tarlinton L, et al.
J Med Imaging Radiat Oncol
. 2011 Aug;
55(4):379-90.
PMID: 21843173
Unlabelled: INTRODUCTION (PURPOSE OF THE STUDY): The objective of this study was to assess whether dual-time-point (18)F-fluoro-2-deoxyglucose ((18)F-FDG)-PET/CT imaging improved the evaluation of suspected malignancy and if there was any...